LakeShore Biopharma Co., Ltd.
PublicLast Round
M&A
Nov 4, 2025
Est. Valuation
$37M
Total Funding Raised
$334M
Company Overview
LakeShore Biopharma Co., Ltd. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes vaccines and therapeutic biologics for infectious diseases and cancer.
Sector
Healthcare
AI Layer
Non-AI
Keywords
biopharmarabies vaccinevaccine developmentPIKA technology platforminfectious disease vaccinebiotechtherapeutic biologicsimmuno-oncologyB2Gcancer immunotherapyvaccine adjuvantclinical developmentHepatitis B vaccinegovernment contractsaluminum-free vaccinetake-private transaction
LakeShore Biopharma Co., Ltd. Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
LakeShore Biopharma Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Nov 4, 2025 | ||||
| Private Placement | Jul 8, 2025 | ||||
| Private Placement | Feb 9, 2024 | ||||
| M&A | Mar 16, 2023 | ||||
| PIPE | Mar 16, 2023 | ||||
Debt | Mar 16, 2022 |
LakeShore Biopharma Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Haitong International Securities Group | Series B |
| Hillhouse Investment | Series B |
| MSA Capital | Series B |
| F-Prime Capital | Series B |
| AIHC | Series B |
| HaiTong XuYu International Limited | Series A |
| CBC Group | Debt |
LakeShore Biopharma Co., Ltd. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |